ChitiA., FantiS., SavelliG., RomeoA., BellanovaB., RodariM., Van GraafeilandB.J., MonettiN., BombardieriE.: Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumors. Eur. J. Nucl. Med., 25: 1395–1403, 1998.
2.
FerrariL., SeregniE., MartinelliA., Van GraafeilandB., Nerini-MolteniS., BottiC., ArtaleS., CrestaS., BombardieriE.: Chromogranin A measurement in neuroendocrine tumors. Int. J. Biol. Markers, 13: 3–9, 1998.
3.
JansonE.T., HolmbergL., StridsbergM., ErikssonB., TheodorssonE., WilanderE., ObergK.: Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann. Oncol., 8: 685–690, 1997.
4.
KrenningE.P., KwekkeboomD.J., de JongM., VisserT.J., ReubiJ.C., BakkerW.H., KooijP.P.: Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide. Semin. Oncol., 21(Suppl. 13): 6–14, 1994.
5.
LambertsS.W., BakkerW.H., ReubiJ.C., KrenningE.P.: Somatostatin receptor imaging in the localization of endocrine tumours. N. Engl. J. Med., 323: 1246–1249, 1990.
6.
ObergK.: Neuroendocrine gastrointestinal tumours. Ann. Oncol., 7: 453–463, 1996.
7.
SeregniE., ChitiA., BombardieriE.: Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur. J. Nucl. Med., 25: 639–658, 1998.
8.
StridsbergM., ObergK., LiQ., EngstromU., LundqvistG.: Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J. Endocrinol., 144: 49–59, 1995.
